Connected health has been the long-held panacea for  reviving the healthcare sector, guiding it smoothly  through a transition to the digital age. Pharmaceutical  companies, healthcare practitioners, technology companies,  government officials, academics, and other stakeholders  had been keenly discussing the digital-health opportunity  even before the unveiling of the Affordable Care Act in the  US in 2010, which established outcomes as an important  measure of care and reimbursement and incorporated digital  technologies as a medium for offering the physically and  socially constrained greater access to care. Given the legacy  challenges the life sciences sector faces – from regulatory  issues to sluggish innovation to drawn-out approval  processes – transformation of healthcare has been slow to  get off the ground. In contrast, the behaviors of consumers  and patients have shifted dramatically over the past 18  months in reaction to the COVID-19 pandemic: openness to  the adoption and use of digital technologies in a healthcare  setting has accelerated rapidly. Can biotechnology and  pharmaceutical (biopharma) companies capitalize on this  momentum to transform and scale their connected health  portfolios? Are we finally approaching the tipping point at  which connected health is sufficiently mature to drive lasting  healthcare transformation?